Chemogenics Biopharma, LLC
Durham, NC
Company facts
- FY2025 rankings
- Self-certified in SAM.gov
- Entity structure
- Sole Proprietorship
- SAM.gov registration date
- Physical address
- 3325 Durham-Chapel Hill Blvd, Durham, NC 27707, USA
- Website
- chemogenicsbiopharma.com
- Founded
- 2008
- Employees
- 1-10
- Estimated annual revenue
- $0-$1M
- Industry
-
- Health Care
- Pharmaceuticals, Biotechnology & Life Sciences
- Pharmaceuticals
- SIC code
- 28 Chemical & Allied Products
- Profiles
Registration and certifications come from SAM.gov and the SBA; company details from public web sources. Updated .
Contract obligations by fiscal year
| Fiscal year | Obligated |
|---|---|
| FY2027 To date | $0 |
| FY2026 | $0 |
| FY2025 | $101,000 |
| FY2024 | $240,000 |
| FY2023 | -$1,360 |
Contract awards
Latest 5 listed here. See the rest on GovTribe.
Similar vendors
About the company
Chemogenics Biopharma, LLC is a for-profit limited liability company based in Durham, North Carolina that specializes in providing custom chemical synthesis and bioanalytical services to support pharmaceutical and medical research institutions. Registered in the System for Award Management since April 2011, the company has established itself as a trusted vendor for federal agencies seeking specialized expertise in small molecule drug development and characterization. Chemogenics Biopharma operates as a sole proprietorship and has developed a proven track record of performance on similar projects across multiple National Institutes of Health (NIH) agencies, positioning itself as a preferred contractor for translational research initiatives.
Chemogenics Biopharma's federal contract portfolio demonstrates deep specialization in synthetic chemistry and pharmacokinetic analysis services, with a total federal contract award history of approximately $614,040 across four major purchase orders. The National Center for Advancing Translational Sciences (NCATS) and the National Institute on Drug Abuse (NIDA) have been primary funding agencies, awarding the company contracts for the custom synthesis and bioanalytical analysis of small molecule compounds, particularly those targeting methyltransferases implicated in disease, with deliverables including compounds at specified purity levels (greater than 95%) accompanied by comprehensive spectroscopic characterization. Recent work includes a $101,000 firm fixed-price purchase order awarded by NIDA on September 16, 2025, for synthesis of small molecule inhibitors and pharmacokinetic analysis using mouse models across multiple routes of administration, scheduled for completion on July 15, 2026. Additional notable awards include a $240,000 NCATS contract (September 2024) for custom synthesis and bioanalytical services focused on small molecule methyltransferase inhibitors, a $249,500 NIDA purchase order awarded under total small business set-aside designation in March 2022 for synthesis and bioanalytical analysis support in microbiome, neurodegeneration, and addiction therapeutic areas, and a $23,540 NCATS contract (September 2023) for pharmacokinetic evaluation of aldometanib in mice. All of Chemogenics Biopharma's documented federal contract awards have been direct prime awards with no subcontracting relationships noted, and the majority have been awarded through simplified acquisition procedures without small business set-asides, with the exception of the 2022 NIDA contract utilizing total small business set-aside designation.
Quick answers
Is Chemogenics Biopharma, LLC registered in SAM.gov?
Yes. Chemogenics Biopharma, LLC's SAM.gov registration is active through October 26, 2027.
What is Chemogenics Biopharma, LLC's CAGE code?
Chemogenics Biopharma, LLC's CAGE code is 6C8M1, and its Unique Entity ID (UEI) is MQLWQEJKQLR3.
How much has Chemogenics Biopharma, LLC received in federal contracts?
Federal contracts obligated $101,000 to Chemogenics Biopharma, LLC in fiscal year 2025 and $339,640 in fiscal years 2023 through 2027.
How does Chemogenics Biopharma, LLC rank among federal contractors?
Chemogenics Biopharma, LLC ranked #27 in PSC B504 in FY2025.
What is Chemogenics Biopharma, LLC's most recent federal award?
Chemogenics Biopharma, LLC's most recent federal contract award is Award. Synthesis and bioanalytical analysis of small molecules for the ncats early translational branch chemistry… (75N95025P00412), from National Institute on Drug Abuse (NIH), on September 16, 2025.
On GovTribe
See Chemogenics Biopharma, LLC's full federal record
- Federal contract awards
- Funding analysis by agency, NAICS and set-aside
- Similar vendors